RxDoctor Payments Data

Matthey Harris, MD

Endocrinology, Diabetes & Metabolism · Gainesville, GANPI 1043213176

Payments from drug & device makers

$1,327in general payments, 2019–2025

Across 35 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$213
  • Insulet Corporation$190
  • Medtronic$145
  • BETA Bionics, Inc.$141
  • Sequel Med Tech, LLC$104
  • Tandem Diabetes Care, Inc.$101
  • plus $434 from 10 others

What the payments were for

  • Food & beverage$1,23193%
  • Education$373%
  • Gifts$594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,327 in reported general payments places this provider in the 30th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$578,436
Medicare patients
1,060
Services billed
34,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide362$447,041
MounjaroTirzepatide349$424,669
TrulicityDulaglutide174$240,727
JardianceEmpagliflozin216$220,261
IsturisaOsilodrostat Phosphate12$216,245
Soliqua 100-33Insulin Glargine/Lixisenatide141$134,154
FarxigaDapagliflozin Propanediol145$123,827
RybelsusSemaglutide71$95,370
Tresiba Flextouch U-100Insulin Degludec124$85,119
Tresiba Flextouch U-200Insulin Degludec56$73,911
JanuviaSitagliptin Phosphate58$61,150
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog73$57,266
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$55,450
Humalog Kwikpen U-200Insulin Lispro19$51,363
SynthroidLevothyroxine Sodium497$46,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$19$697,432619 claims
Novo NordiskOzempic, Rybelsus, Novolog$12$561,328492 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$61$134,154141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →